Novel melanoma therapy

Table 1 Recent targeted therapy study results in melanoma

Study	Agent(s)	Phase of study	Median PFS (months)	OS	ORR (%)
[4]	Dabrafenib + trametinib	II	9.4	79 % at 1 year	76
[4]	Dabrafenib	II	5.8	70 % at 1 year	54
[16] [17]	Dabrafenib + trametinib	III	11.0	25.1 months	67
[16] [17]	Dabrafenib	III	8.8	18.7 months	51
[18]	Dabrafenib + trametinib	III	11.4	72 % at 1 year	64
[18]	Vemurafenib	III	7.3	65 % at 1 year	51
[19] [20]	Cobimetinib + vemurafenib	I/II	Vemurafenib refractory: 2.8	8.4 months	15
[19] [20]	Cobimetinib + vemurafenib	I/II	Vemurafenib naïve: 13.7	28.5 months	87
[21] [22]	Cobimetinib + vemurafenib	III	12.3	81 % at 9 months	70
[21] [22]	Vemurafenib	III	7.3	73 % at 9 months	50
[23]	Encorafenib + binimetinib	I/II	11.3	NA	74.5
[24]	Binimetinib	III	NA	NA	15
[24]	DTIC	III	NA	NA	7

ISSN: 2162-3619